title: [Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma].
abstract: A computer database was created to take care of a wide range of protocols for combined treatment of Hodgkin's disease stage I-IV (n=1,573). Early-onset radiation-related injuries (pneumonitis) and exposure of lung tissues to radiation were identified as the main risk factors for cardiopathology development. It is suggested that total focal dosage used after chemotherapy be reviewed since total dosage for the entire lymph collector in excess of 30 Gy might contribute to hazards of cardiopathology. However, a locally administered TTD ranging 36-44 Gy to deal with residual tumor offers best advantage in preventing local relapse. Nor does it increase the risk of future complications. Our approach might promote individualization of prognosis as far as cardiac complications involved in Hodgkin's lymphoma are concerned.
authors: P N
authors: PN
authors: Podol'skiĭ
authors: P V
authors: PV
authors: Datsenko
authors: G A
authors: GA
authors: Pan'shin
authors: V M
authors: VM
authors: Sotnikov
authors: Iu D
authors: IuD
authors: Mel'nik
authors: A V
authors: AV
authors: Ivashin
authors: V K
authors: VK
authors: Bozhenko
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D005260:Female; D006321:Heart / Q000528:radiation effects*; D006331:Heart Diseases / Q000209:etiology* / Q000401:mortality; D006338:Heart Neoplasms / Q000556:secondary; D006689:Hodgkin Disease / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011014:Pneumonia / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D018570:Risk Assessment; D012307:Risk Factors; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone